Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients.
about
The survival outcomes following liver transplantation (SOFT) score: validation with contemporaneous data and stratification of high-risk cohorts.Pre-operative risk factors predict post-operative respiratory failure after liver transplantation.Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) eraPredictive factors of neurological complications and one-month mortality after liver transplantation.Role of MELD score and serum creatinine as prognostic tools for the development of acute kidney injury after liver transplantation.Liver transplantation in Greek children: 15 years experience.The combination of MELD score and ICG liver testing predicts length of stay in the ICU and hospital mortality in liver transplant recipients.Comparison of the Child-Turcotte-Pugh classification and the model for end-stage liver disease score as predictors of the severity of the systemic inflammatory response in patients undergoing living-donor liver transplantationSurgical management of hepatic malignancy.Use of Renal Replacement Therapy May Influence Graft Outcomes following Liver Transplantation for Acute Liver Failure: A Propensity-Score Matched Population-Based Retrospective Cohort Study.Liver transplantation as ultimate tool to treat portal hypertension.Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignanciesLiver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5.Living donor liver transplantation for high model for end-stage liver disease score: What have we learned?Racial/ethnic disparities in liver transplant surgery and hospice use: parallels, differences, and unanswered questions.Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.A prospective cohort study of risk prediction in simultaneous pancreas and kidney transplantation.Critical care of the end-stage liver disease patient awaiting liver transplantation.Pharmacokinetics of antidepressants in patients with hepatic impairment.Adult Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure in High-Model for End-Stage Liver Disease Score Patients.Catheter-measured Hemodynamics of Adult Fontan Circulation: Associations with Adverse Event and End-organ Dysfunctions.Superior Mesenteric Arterial Flow Pattern is Associated with Major Adverse Events in Adults with Fontan Circulation.Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C.Evaluation of neutrophil/leukocyte ratio and organ failure score as predictors of reversibility and survival following an acute-on-chronic liver failure event.A novel prognostic score for acute-on-chronic hepatitis B liver failure.Regional variation and use of exception letters for cadaveric liver allocation in children with chronic liver disease.Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients?Predictive indices of morbidity and mortality after liver resection.MELD and other factors associated with survival after liver transplantation.A validated model for predicting outcome after liver transplantation: implications on transplanting the extremely sick.Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis.Short-term postliver transplant survival after the introduction of MELD scores for organ allocation in the United States.Risk Assessment in High- and Low-MELD Liver Transplantation.Liver transplantation in patients with end-stage liver disease requiring intensive care unit admission and intubation.Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience.Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients.Respiratory risk score for the prediction of 3-month mortality and prolonged ventilation after liver transplantation.Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation.Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema.
P2860
Q30652056-97E96DE2-6D53-4FAC-ACA4-315E38725AEFQ33988500-AB24FD3E-595F-4F42-8D35-D04634D1AE73Q34362803-1CD2C8DD-2E31-462C-8819-1F7A84D398CFQ34722166-8DA34A63-2173-4785-8661-BDC0E6B4388FQ34745144-5D4AC29D-73BF-428F-BBDE-0B2855FED149Q34979471-E3AC7BE7-A047-4E78-B3E3-A9E5C504A6D7Q35257636-85F56DCF-9946-45EB-9455-81E441BF6412Q35333828-7191F21E-1D02-4852-BA05-CF1023ED9F2AQ35806757-07298897-6FB0-4EE9-9AD2-7B261AB3D403Q35941418-30C3468B-5CFA-48D4-A2CC-2A927EC7399FQ36141452-058E98BE-4463-41B3-A61A-BEB9EA8EEC1DQ36656612-9520AE1C-A2D4-42D1-B968-78E708C73EC4Q36702287-2D95A07F-B5A2-4CDE-ADF2-4B45C83C1D00Q37157053-41906EFC-1F49-41D4-A71C-4B128DC8B685Q37157115-3582704D-66F5-4A11-995E-731680CFDB10Q37212974-00DE46C2-1749-4675-BC6C-16BA5B2C5CFBQ37447772-8EC30FAB-2DA8-4871-822B-27C9F8CAEA05Q37867071-3EFD085C-939E-46D0-B32C-567762A102F7Q38253564-6430001E-604C-4A95-B5E1-666760DA9C7FQ38406667-603BC3BC-496F-4E8F-B64B-91E554CC47C6Q38756935-438BB7D1-E7CB-4ADB-8114-AC22AB570338Q38795075-5B56CCC4-D41C-4FBF-9FC9-D5B11B162798Q40196672-31CAE046-82AC-44DA-8A81-C858AE1FD9C3Q41020332-C7BBF201-1B62-47E0-A981-589E14A642E8Q41489217-5B087219-72DF-4840-88BF-0B6C81CF4B55Q42661520-AEA9D07B-C695-4BD7-934C-B4F5B73A0513Q43554481-2C2D42CD-1474-44ED-8BC3-C52AA728240CQ44032755-ACFA61EE-CC79-4E75-B178-202B28EA8C2DQ44394558-D6AF1F97-DF19-4C25-A922-61A676673B33Q44912598-FE891D86-E8A9-4498-AF14-7006F8E4C6AAQ44968476-84A3D9D5-AD00-4A75-A080-B33438E66F53Q45151590-E9912673-40AD-473E-BCC0-E514392C70D9Q46504430-F97D7F15-E395-484A-9C57-8B8A63A255A8Q46711215-6C6F876A-A81B-49AB-95B7-C15BC88A2C68Q47684606-0FCDD274-ACD8-4D27-84D7-91F4A2400DDDQ48097471-7CBE48B4-5AAB-4A30-9F6D-6C28F906C9DEQ50449764-A2B50A8D-576F-494F-8253-2F5E7CF3B54BQ50490792-70610534-489C-4FAE-877F-470D4CD5CB3BQ51346002-959FCF40-8B7E-4BEB-A328-C36237D55558Q51623426-6E560D30-380D-45A5-8E5E-4C5AAE0DAFE5
P2860
Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Model for end-stage liver dise ...... an Sharing status 2A patients.
@en
type
label
Model for end-stage liver dise ...... an Sharing status 2A patients.
@en
prefLabel
Model for end-stage liver dise ...... an Sharing status 2A patients.
@en
P2093
P2860
P356
P1476
Model for end-stage liver dise ...... an Sharing status 2A patients.
@en
P2093
Dianne L Rudow
Jean C Emond
K Shiva Kumar
Mark W Russo
Milan Kinkhabwala
Patricia Harren
Robert S Brown
Steven Lobritto
P2860
P304
P356
10.1053/JLTS.2002.31340
P577
2002-03-01T00:00:00Z